The New York Times report on Eli Lilly's retatrutide highlights average 28% body weight reduction after 80 weeks, yet this figure stems from company announcements rather than fully published peer-reviewed RCTs with detailed adverse event profiles. Phase 2 data in NEJM (Jastreboff et al., 2023; n=338, randomized, double-blind) showed dose-dependent losses up to 24% at 48 weeks for the triple agonist targeting GLP-1, GIP, and glucagon receptors, but lacked long-term cardiovascular outcomes and had industry funding conflicts. Observational real-world studies on semaglutide (e.g., Wilding et al., STEP trials) reveal 15-20% losses with high discontinuation rates due to GI effects, a pattern likely extending to retatrutide. Original coverage overlooks sustainability post-treatment, equity in access, and direct comparisons to tirzepatide (SURMOUNT-1 RCT, n=2539). Larger phase 3 trials are essential to confirm efficacy beyond early signals.